ISA Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- ISA Pharmaceuticals's estimated annual revenue is currently $1.1M per year.
- ISA Pharmaceuticals's estimated revenue per employee is $155,000
Employee Data
- ISA Pharmaceuticals has 7 Employees.
- ISA Pharmaceuticals grew their employee count by -89% last year.
ISA Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | CMC Project Manager | Reveal Email/Phone |
ISA Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is ISA Pharmaceuticals?
ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The Company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT®technology. SLP®immunotherapies are designed to fully harness and direct the body's own defenses towards fighting the disease. In December 2017, ISA Pharmaceuticals closed a clinical immuno-oncology collaboration with Regeneron to advance its SLP®lead compound ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with cemiplimab (REGN2810, Libtayo®), a PD-1 (programmed cell death protein 1) antibody in development by Regeneron, which was recently approved by the FDA as monotherapy for patients with advanced cutaneous squamous cell carcinoma. ISA develops a diverse SLP®immunotherapy portfolio targeting unmet medical needs in cancer and chronic infections, including tailored therapy for rare diseases. ISA´s most advanced clinical-stage immunotherapeutic is ISA101, an SLP® immunotherapy targeting human papillomavirus (HPV)-induced diseases. It is currently in clinical development in advanced and recurrent cervical cancer, incurable HPV16-postive solid tumors and anal intraepithelial neoplasia (AIN). Clinical proof-of-concept has been established in vulvar intraepithelial neoplasia (VIN), a pre-cancerous disease caused by HPV. The company was founded in 2004 by Aglaia Oncology Fund and is based in Leiden, The Netherlands. For more information, please visit www.isa-pharma.com SLP® and AMPLIVANT® are registered trademarks in Europe.
keywords:N/AN/A
Total Funding
7
Number of Employees
$1.1M
Revenue (est)
-89%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ISA Pharmaceuticals News
Regeneron Pharmaceuticals has agreed to acquire Checkmate ... cervical cancer in combination with ISA Therapeutics' ISA101b (all Phase II).
ISA Pharmaceuticals BV; Merck and Co. Inc. Serum Institute of India Pvt. Ltd. Walvax Biotechnology Co. Ltd. Xiamen Innovax Biotech Co. Ltd...
A clinical trial of Amplivant an adjuvant technology to boost immune response to cancer therapy has started. ISA Pharmaceuticals' novel...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.9M | 7 | 17% | N/A |
#2 | $1.4M | 7 | 17% | N/A |
#3 | $1.7M | 11 | 10% | N/A |
#4 | $3.8M | 16 | 129% | $104M |
#5 | $3.3M | 18 | 6% | N/A |